Responsible and accountable for executing program-level new chemical entity Medicinal Chemistry strategy to deliver preclinical development candidates to meet Shire’s portfolio objectives. Integrates activities with other groups within Discovery Therapeutics (e.g. Protein Production and Analytics) and other major functions in Shire (e.g. Discovery Biology and Pharmaceutical Sciences) to ensure highly collaborative cross-functional research execution. Major functions supported within Discovery Chemistry include medicinal chemistry, Discovery program leadership, and management of external CRO resources. Effectively engages and directs CRO partners in the execution of discovery chemistry research. Capable of representing the Company in all chemistry related technical matters of significance.
Responsibilities (% of time):
Preclinical Program Leadership: Responsible and accountable for the advancement of small molecule discovery programs spanning Hit-to-Lead, Lead-ID and Lead Optimization discovery stages. This will include the identification of lead candidates using a variety of technologies, and optimization of these to deliver preclinical development candidates that meet or exceed prospectively set criteria. Responsible for providing pharmacological tools that enable preclinical proof-of-concept validation studies. Effectively engages in collaboration between Shire internal functions and CRO partners.
Support additional therapeutic modalities (e.g. oligonucleotides, and molecular conjugates) to deliver pharmacological tools and candidates through novel chemistry insights and the production of reagents in support of hypothesis driven research.
- PhD degree in Medicinal Chemistry, or equivalent experience
- 10+ years of experience in the biotechnology or pharmaceutical industry, designing, optimizing and delivering high quality new chemical entity drug candidates.
- Significant experience managing external CROs.
Req ID: R0011173